Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.

TOKYO and SOUTH SAN FRANCISCO, Calif., Dec. 26, 2019 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Xyphos Biosciences, Inc. (CEO: James Knighton, "Xyphos") today announced that Astellas has acquired Xyphos. With the acquisition...

from PR Newswire: https://ift.tt/2EWc2Wg